Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Letizia Foroni

Showing results (21-30 of 84) with videos related to

Pageof 9
Sort By:
British Journal of Haematology|January 7, 2022
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemiaPaolo Gallipoli, Richard E Clark, Jenny Byrne, et al.
Blood|May 31, 2012
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinibDavid Marin, Corinne Hedgley, Richard E Clark, et al.
American Journal of Hematology|June 23, 2009
Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemiaLetizia Foroni, Gareth Gerrard, Emmanuel Nna, et al.
American Journal of Hematology|May 9, 2012
Fast-mode duplex qPCR for BCR-ABL1 molecular monitoring: innovation, automation, and harmonizationGareth Gerrard, Katherine Mudge, Pierre Foskett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemiaMarc R Mansour, Veronique Duke, Letizia Foroni, et al.
Blood|August 14, 2010
Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal responseAya Kuwabara, Anna Babb, Amr Ibrahim, et al.
British Journal of Haematology|March 31, 2018
Recurrent histone mutations in T-cell acute lymphoblastic leukaemiaGrace Collord, Inigo Martincorena, Matthew D Young, et al.
British Journal of Haematology|January 8, 2022
Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?Katherine M Dominy, Simone Claudiani, Matthew O'Hare, et al.
Haematologica|May 13, 2017
E14a2 <i>BCR-ABL1</i> transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapySimone Claudiani, Jane F Apperley, Robert Peter Gale, et al.
British Journal of Haematology|June 5, 2003
Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligandDylan T Jones, Kanagasabai Ganeshaguru, Wayne A Mitchell, et al.
Pageof 9

Showing results (21-30 of 84) with videos related to

Sort By:
Pageof 9
British Journal of Haematology|January 7, 2022
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemiaPaolo Gallipoli, Richard E Clark, Jenny Byrne, et al.
Blood|May 31, 2012
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinibDavid Marin, Corinne Hedgley, Richard E Clark, et al.
American Journal of Hematology|June 23, 2009
Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemiaLetizia Foroni, Gareth Gerrard, Emmanuel Nna, et al.
American Journal of Hematology|May 9, 2012
Fast-mode duplex qPCR for BCR-ABL1 molecular monitoring: innovation, automation, and harmonizationGareth Gerrard, Katherine Mudge, Pierre Foskett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemiaMarc R Mansour, Veronique Duke, Letizia Foroni, et al.
Blood|August 14, 2010
Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal responseAya Kuwabara, Anna Babb, Amr Ibrahim, et al.
British Journal of Haematology|March 31, 2018
Recurrent histone mutations in T-cell acute lymphoblastic leukaemiaGrace Collord, Inigo Martincorena, Matthew D Young, et al.
British Journal of Haematology|January 8, 2022
Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?Katherine M Dominy, Simone Claudiani, Matthew O'Hare, et al.
Haematologica|May 13, 2017
E14a2 <i>BCR-ABL1</i> transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapySimone Claudiani, Jane F Apperley, Robert Peter Gale, et al.
British Journal of Haematology|June 5, 2003
Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligandDylan T Jones, Kanagasabai Ganeshaguru, Wayne A Mitchell, et al.
Pageof 9